2019 logo_150x35_jpg.jpg
Novan Appoints Brian M. Johnson as Chief Commercial Officer and Receives Conditional FDA Acceptance of Proposed Brand Name KINSOLUS™ for SB206 in Molluscum Contagiosum
November 02, 2021 08:30 ET | Novan, Inc.
– Mr. Johnson brings broad commercial expertise with over 30 years of leadership spanning dermatology marketing, sales, sales management, digital marketing and managed care –– Company received...
2019 logo_150x35_jpg.jpg
Novan Announces Inclusion in Russell Microcap® Index
June 24, 2021 08:05 ET | Novan, Inc.
DURHAM, N.C., June 24, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that as part of the annual reconstitution of the Russell stock indexes, Novan...
2019 logo_150x35_jpg.jpg
Novan Announces Closing of $40 Million Public Offering of Common Stock
June 21, 2021 16:01 ET | Novan, Inc.
DURHAM, N.C., June 21, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company's previously announced underwritten public offering...
2019 logo_150x35_jpg.jpg
Novan Announces Pricing of $40 Million Public Offering of Common Stock
June 17, 2021 09:00 ET | Novan, Inc.
DURHAM, N.C., June 17, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company" or "Novan") (NASDAQ:NOVN) today announced the pricing of the Company's previously announced underwritten public offering...
2019 logo_150x35_jpg.jpg
Novan Announces Proposed Public Offering of Common Stock
June 16, 2021 16:01 ET | Novan, Inc.
DURHAM, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company” or “Novan”) (NASDAQ: NOVN) today announced a proposed underwritten public offering of its common stock (the “Offering”)....
2019 logo_150x35_jpg.jpg
Results from Novan’s Exploratory Studies Further Demonstrate Antimicrobial Effect of NITRICIL™ Platform Technology with NVN4100 in Companion Animal Health
June 07, 2021 08:30 ET | Novan, Inc.
– Positive in vitro results demonstrate antimicrobial effect of NVN4100 against a wide variety of bacteria and suggest a promising bactericidal mode of action – – Novel in vivo canine pyoderma model...
2019 logo_150x35_jpg.jpg
Novan Announces 1-for-10 Reverse Stock Split
May 25, 2021 08:00 ET | Novan, Inc.
DURHAM, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it has filed a Certificate of Amendment to the Restated Certificate of...
2019 logo_150x35_jpg.jpg
Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology
April 22, 2021 09:00 ET | Novan, Inc.
MORRISVILLE, N.C., April 22, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that data from the Company’s previously completed Phase 3 trials of SB206...
2019 logo_150x35_jpg.jpg
Novan Provides Enrollment Update and Announces New Corporate Headquarters
January 19, 2021 09:00 ET | Novan, Inc.
– B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum reaches 90% enrollment with topline data targeted for Q2 2021 – – Company secures new location to serve as corporate headquarters and to...
2019 logo_150x35_jpg.jpg
Novan Exceeds 60% Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
December 15, 2020 09:00 ET | Novan, Inc.
– Completion of patient enrollment targeted for Q1 2021 with readout of topline results targeted for Q2 2021 – – SB206, if approved, has the potential to meet an important need for the treatment of...